Park Ben Ho, Davidson Nancy E
Breast Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA.
Cancer Cell. 2007 Oct;12(4):297-9. doi: 10.1016/j.ccr.2007.10.004.
Trastuzumab is an established therapy for women with breast cancers that overexpress HER2. Despite its proven benefit in treating breast cancer, not all women derive benefit from this monoclonal antibody, and resistant disease can develop. In this issue of Cancer Cell, Berns et al. present evidence that activation of the PI3 kinase pathway, either via loss of the tumor suppressor PTEN or through oncogenic stimulation of PIK3CA, can mediate trastuzumab resistance. This study extends important work of others and forms the rationale for future investigations combining inhibitors of the PI3 kinase pathway in conjunction with trastuzumab therapy.
曲妥珠单抗是治疗HER2过表达乳腺癌女性患者的一种成熟疗法。尽管其在治疗乳腺癌方面已证实具有益处，但并非所有女性都能从这种单克隆抗体中获益，且可能会出现耐药性疾病。在本期《癌细胞》杂志中，伯恩斯等人提供证据表明，通过肿瘤抑制因子PTEN缺失或PIK3CA的致癌性刺激激活PI3激酶途径，可介导曲妥珠单抗耐药。这项研究扩展了其他人的重要工作，并为未来将PI3激酶途径抑制剂与曲妥珠单抗疗法联合使用的研究提供了理论依据。
